Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Amarin Corporation plcNASDAQ: AMRN
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 8.9% from a year ago
Short-term investments stood at $176.76M at the end of Q1 FY2026, up 8.9% from a year earlier and up 5.3% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.
Context
- Short-term investments amounted to 27.4% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +8.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 167.93M USD
- Year-over-year change
- -3.0%
- 4-year CAGR
- -8.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 167.93M | -3.0% |
| FY2024 | 2024-12-31 | 173.18M | +42.6% |
| FY2023 | 2023-12-31 | 121.41M | +32.4% |
| FY2022 | 2022-12-31 | 91.7M | -60.9% |
| FY2021 | 2021-12-31 | 234.67M | — |
Short-term Investments vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +8.9% is the 4th highest of 9, against a peer median of -3.4%.
- Short-term investments amounts to 27.4% of total assets for AMRN, versus a peer median of 43.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $233.94M USD | +132.3% | +46.0% | 69.7% | |
ENGNenGene Holdings Inc. | Apr 2026 | $228.64M USD | +43.0% | — | 74.3% |
| Mar 2026 | $176.76M USD | +8.9% | +22.3% | 27.4% | |
| Mar 2026 | $163.25M USD | -9.7% | -28.7% | 46.6% | |
| Mar 2026 | $150.66M USD | +32.1% | +163.8% | 52.1% | |
| Mar 2026 | $64.42M USD | -10.1% | +65.4% | 56.0% | |
| Mar 2026 | CHF 55.63M CHF | -55.7% | -10.8% | 40.5% | |
| Mar 2026 | $52.27M USD | +2.9% | +41.3% | 28.5% | |
| Mar 2026 | $22.47M USD | -83.5% | -17.5% | 10.8% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding AMRN) | — | -3.4% | +41.3% | 43.5% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 219.45M | 217.67M | 199.25M | 121.04M | 134.86M |
| Short-term Investments | 234.67M | 91.7M | 121.41M | 173.18M | 167.93M |
| Net Receivables | 163.65M | 130.99M | 133.56M | 122.28M | 126.83M |
| Inventory | 234.68M | 228.73M | 258.62M | 166.05M | 195.91M |
| Other Current Assets | 3.92M | 20.02M | 525K | 12.85M | 24.35M |
| Total Current Assets | 878.73M | 689.1M | 724.98M | 595.4M | 649.88M |
| Property, Plant & Equipment (Net) | 9.09M | 9.95M | 8.42M | 7.61M | 6.47M |
| Goodwill | 0 | 0 | 0 | 0 | 13.36M |
| Intangible Assets | 23.55M | 21.78M | 19.3M | 16.39M | 0 |
| Long-term Investments | 35M | 1.28M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 121.71M | 164.08M | 78.98M | 65.95M | 1.06M |
| Total Non-current Assets | 189.34M | 197.08M | 106.7M | 89.95M | 20.89M |
| Total Assets | 1.07B | 886.18M | 831.68M | 685.35M | 670.77M |
| Account Payables | 114.92M | 64.6M | 52.76M | 40.37M | 45.35M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.65M | 2.2M | 2.34M | 0 | 0 |
| Other Current Liabilities | 45.6M | 35.64M | 185.23M | 17.55M | 149.1M |
| Total Current Liabilities | 370.68M | 259.48M | 259.28M | 179.95M | 194.46M |
| Long-term Debt | 0 | 0 | 0 | 0 | 6.08M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.06M | 13.15M | 2.51M | 0 | 0 |
| Other Non-current Liabilities | 7.65M | 8.21M | 9.06M | 11.5M | 4.87M |
| Total Non-current Liabilities | 30.28M | 31.37M | 20.31M | 19.22M | 17.03M |
| Total Liabilities | 400.97M | 290.85M | 279.59M | 199.17M | 211.49M |
| Common Stock | 294.03M | 299M | 302.76M | 305.3M | 310.18M |
| Retained Earnings | (1.42B) | (1.53B) | (1.59B) | (1.67B) | (1.71B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 667.1M | 595.33M | 552.1M | 486.18M | 459.28M |
| Total Debt | 8.58M | 10.02M | 8.74M | 7.72M | 12.16M |
| Net Debt | (210.88M) | (207.65M) | (190.52M) | (113.32M) | (122.7M) |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.